Personal information

Activities

Works (4)

Anakinra Efficacy in COVID-19 Pneumonia Guided by Soluble Urokinase Plasminogen Activator Receptor: Association With the Inflammatory Burden of the Host

International Journal of Antimicrobial Agents
2025 | Journal article
EID:

2-s2.0-85213049221

Part of ISSN: 18727913 09248579
Contributors: Kyriazopoulou, E.; Akinosoglou, K.; Florou, E.; Kouriannidi, E.; Bogosian, A.; Tsachouridou, O.; Syrigos, K.N.; Gatselis, N.; Milionis, H.; Papanikolaou, I.C. et al.
Source: Self-asserted source
Eleni Florou via Scopus - Elsevier
grade
Preferred source (of 2)‎

Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Nature Medicine, (2021), 27, 10, (1752-1760), 10.1038/s41591-021-01499-z)

Nature Medicine
2021 | Journal article
EID:

2-s2.0-85116537685

Part of ISSN: 1546170X 10788956
Contributors: Kyriazopoulou, E.; Poulakou, G.; Milionis, H.; Metallidis, S.; Adamis, G.; Tsiakos, K.; Fragkou, A.; Rapti, A.; Damoulari, C.; Fantoni, M. et al.
Source: Self-asserted source
Eleni Florou via Scopus - Elsevier

Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor

medRxiv
2021 | Other
EID:

2-s2.0-85108388399

Contributors: Kyriazopoulou, E.; Poulakou, G.; Milionis, H.; Metallidis, S.; Adamis, G.; Tsiakos, K.; Fragkou, A.; Rapti, A.; Damoulari, C.; Fantoni, M. et al.
Source: Self-asserted source
Eleni Florou via Scopus - Elsevier

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nature Medicine
2021 | Journal article
EID:

2-s2.0-85114635853

Part of ISSN: 1546170X 10788956
Contributors: Kyriazopoulou, E.; Poulakou, G.; Milionis, H.; Metallidis, S.; Adamis, G.; Tsiakos, K.; Fragkou, A.; Rapti, A.; Damoulari, C.; Fantoni, M. et al.
Source: Self-asserted source
Eleni Florou via Scopus - Elsevier